Biopharmaceutical company focused on developing therapies for liver and other chronic diseases.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing therapies aimed at treating liver and other chronic diseases. Founded in 1988 and headquartered in Newark, California, the company is actively developing innovative treatments to address significant medical challenges.
At the forefront of CymaBay's pipeline is seladelpar (MBX-8025), its lead product candidate. Seladelpar functions as a selective agonist of peroxisome proliferator activated receptor delta and is currently undergoing Phase III clinical trials for the treatment of primary biliary cholangitis (PBC). The compound has also completed Phase 2b clinical studies targeting nonalcoholic steatohepatitis, a condition with significant unmet medical needs.
In addition to seladelpar, CymaBay is advancing MBX-2982 through Phase 2a clinical trials. This therapy is specifically designed for addressing hypoglycemia in individuals with type 1 diabetes, further demonstrating the company's commitment to developing therapies that tackle diverse disease indications.
CymaBay Therapeutics operates with strategic collaborations to bolster its research and development efforts. It has a license agreement with ABW Cyclops SPV LP to support seladelpar's development for PBC treatment. Furthermore, the company holds a worldwide license from Janssen Pharmaceuticals, Inc. to explore and commercialize compounds targeting an undisclosed metabolic disease target, underscoring its broad research scope and potential future therapeutic expansions.